ATYR aTyr Pharma, Inc. - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 7, 2026ATYR Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
ATYR Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 1 de Julho de 2019 | 1-for-14 | Reverso |
Sobre aTyr Pharma, Inc. - Common Stock Visão geral da empresa da Wikipedia
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
History
In 2005, aTyr was founded by Paul Schimmel, and Xiang-Lei Yang, two aminoacyl tRNA synthetase scientists at The Scripps Research Institute. In 2009, Bruce Beutler, recipient of the 2011 Nobel Prize in Physiology or Medicine, joined aTyr as a member of the scientific advisory board.
In April 2007, Polaris Partners and Alta Partners co-led a $10.5 million Series B financing. In October 2010, Series C financing totaled $23 million and was led by Domain Associates. This round was followed by a $49 million Series D in August 2013.
aTyr was a winner of the 2011 Red Herring 100 North America Award for discovering and developing innovative medicines based on Physiocrine biology.
In April 2015, aTyr raised $76 million in a Series E, led by Sofinnova Ventures, and filed for an IPO. The company began trading as LIFE on the Nasdaq stock exchange.
ATyr's primary focus is on ATYR1923, a clinical stage product candidate which binds to the NRP2 receptor and is designed to down regulate immune engagement in interstitial lung diseases (ILDs). ATYR1923 is currently being investigated in a clinical trial in patients with pulmonary sarcoidosis. In January 2020, ATyr entered into a license with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. Under the license agreement, Kyorin received an exclusive right to develop and commercialize ATYR1923 in Japan for all forms of ILDs including, sarcoidosis, chronic hypersensitivity pneumonitis (CHP) and connective tissue disease ILD (CTD-ILD). aTyr recently initiated a clinical trial for ATYR1923 in patients with severe respiratory complications related to COVID-19.
Therapeutic concept
Homeostasis, or the coordinated regulation of tissues within the body, is fundamental to the maintenance of the overall health of an organism. Lack of homeostasis can lead to disease and death. The process of homeostasis was first described in 1865 by the French physiologist Claude Bernard and Walter Cannon later coined the term. In the 150 years since this discovery, many proteins associated with homeostatic pathways have been discovered, ranging from insulin to erythropoietin.
aTyr was founded after Dr. Schimmel discovered several nontranslational functions of aminoacyl tRNA synthetases, which are primarily responsible for the production of a vital component of protein synthesis, aminoacyl-tRNAs. [23] These nontranslational functions have since been shown to play an important role in maintaining homeostasis. [23] One of these nontranslational functions is modulation and regulation of the immune response. [23] This modulatory activity is a result of Physiocrines, a novel class of proteins that are present as biologically active signaling regions of the tRNA synthetases. aTyr's research is based on the premise that Physiocrines are involved in orchestrating homeostatic activities to help the body restore diseased or damaged tissue to a healthier state.
By researching and understanding the role of Physiocrines in immune modulation, aTyr has developed two IND candidates.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | ATYR | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E | -0.4média 5A ≈-2.5 | ≈-2.5 | · | · | |
| P/S | 148.2média 5A ≈489.4 | ≈489.4 | 60.5 | Sobreavaliado | |
| P/B (MRQ) | 0.6média 5A ≈1.9 | ≈1.9 | · | · | |
| Preço / FCF (TTM) | -0.5média 5A ≈-3.1 | ≈-3.1 | · | · | |
| Preço / Fluxo de Caixa (TTM) | -0.5média 5A ≈-3.2 | ≈-3.2 | · | · | |
| Price / Tangible Book (Preço / Valor Patrimonial Tangível) | 0.4média 5A ≈1.9 | ≈1.9 | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | ATYR | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Operating Margin (Margem Operacional) | -40856.3%média 5A ≈-21440.1% | ≈-21440.1% | -1518.6% | Fraco | |
| EBITDA Margin (Margem EBITDA) | -40506.8%média 5A ≈-21234.9% | ≈-21234.9% | -1473.1% | Fraco | |
| Pretax Margin (Margem de Impostos Pré-Tributação) | -39012.1%média 5A ≈-20242.1% | ≈-20242.1% | · | · | |
| Net Profit Margin (Margem de Lucro Líquido) | -39009.5%média 5A ≈-20241.1% | ≈-20241.1% | -178.5% | Fraco | |
| ROA | -78.1%média 5A ≈-54.0% | ≈-54.0% | -66.7% | Abaixo da média | |
| ROE | -107.8%média 5A ≈-69.5% | ≈-69.5% | -46.5% | Abaixo da média | |
| ROIC | -115.0%média 5A ≈-73.7% | ≈-73.7% | -60.4% | Fraco |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | ATYR | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Índice de liquidez corrente (MRQ) | 5.1média 5A ≈8.4 | ≈8.4 | 2.0 | Liquidez forte | |
| Quick Ratio (Índice de Liquidez Seca) | 0.7média 5A ≈0.8 | ≈0.8 | 1.1 | Liquidez forte |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | ATYR | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | -19.1%média 5A ≈-49.7% | ≈-49.7% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | -73.7% | · | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | -55.1% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | ATYR | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.0média 5A ≈0.0 | ≈0.0 | 0.0 | Fraco | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$3.3K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 12, 2026 | $-0.11 | $-0.12 | 11.2% |
| 31 de Março de 2026 | Mai 15, 2026 | $-0.11 | $-0.14 | 21.6% |
| 31 de Dezembro de 2025 | $-0.14 | $-0.19 | 25.3% | |
| 30 de Setembro de 2025 | $-0.26 | $-0.19 | -38.8% | |
| 30 de Junho de 2025 | $-0.22 | $-0.19 | -17.0% | |
| 31 de Março de 2025 | $-0.17 | $-0.19 | 12.3% | |
| 31 de Dezembro de 2024 | $-0.18 | $-0.23 | 21.9% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10M | $0 | $10M | $422.0K | |
| R&D Expense | $60M | $54M | $42M | $43M | $23M | $17M | $14M | |
| SG&A Expense | $18M | $14M | $13M | $14M | $11M | $9M | $9M | |
| Operating Expenses | $78M | $68M | $55M | $57M | $34M | $26M | $23M | |
| Operating Income | $-78M | $-68M | $-55M | $-46M | $-34M | $-16M | $-23M | |
| Other Non-op | $4M | $4M | $5M | $1M | $238.0K | $-319.0K | $-785.0K | |
| Pretax Income | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-24M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-16M | |
| EPS (Basic) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · | |
| EPS (Diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · | |
| Shares (Basic) | 92,985,359 | 74,261,265 | 53,606,488 | 28,419,569 | 19,080,878 | 9,160,269 | · | |
| Shares (Diluted) | 92,985,359 | 74,261,265 | 53,606,488 | 28,419,569 | 19,080,878 | 9,160,269 | · | |
| EBITDA | $-77M | $-67M | $-54M | $-46M | $-34M | $-15M | $-22M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $11M | $23M | $10M | $2M | $17M | $9M | |
| Prepaid Expense | $677.0K | $8M | $2M | $3M | $5M | $2M | $681.0K | |
| Current Assets | $80M | $82M | $103M | $81M | $114M | $36M | $32M | |
| PP&E (Net) | $4M | $5M | $6M | $3M | $543.0K | $899.0K | $1M | |
| PP&E (Gross) | $9M | $9M | $10M | $9M | $7M | $8M | $7M | |
| Accum. Depreciation | $5M | $5M | $5M | $6M | $6M | $7M | $6M | |
| Other Non-current Assets | $148.0K | $66.0K | $131.0K | $193.0K | $158.0K | $213.0K | $172.0K | |
| Total Assets | $93M | $97M | $121M | $96M | $116M | $39M | $36M | |
| Accounts Payable | $4M | $4M | $4M | $3M | $1M | $1M | $847.0K | |
| Accrued Liabilities | $10M | $9M | $12M | $10M | $4M | $4M | $2M | |
| Current Liabilities | $15M | $15M | $16M | $14M | $6M | $6M | $13M | |
| Capital Leases | $10M | $11M | $12M | $10M | $398.0K | $1M | $2M | |
| Total Debt | · | · | · | · | · | · | $9M | |
| Common Stock | $98.0K | $84.0K | $63.0K | $29.0K | $28.0K | $11.0K | $4.0K | |
| Paid-in Capital | $674M | $602M | $559M | $490M | $482M | $370M | $344M | |
| Retained Earnings | $-606M | $-532M | $-468M | $-418M | $-372M | $-339M | $-322M | |
| AOCI | $-8.0K | $-40.0K | $-74.0K | $-433.0K | $-263.0K | $-43.0K | $-40.0K | |
| Stockholders' Equity | $67M | $70M | $91M | $71M | $109M | $32M | $21M | |
| Liabilities + Equity | $93M | $97M | $121M | $96M | $116M | $39M | $36M | |
| Shares Outstanding | 98,031,014 | 84,038,922 | 63,286,404 | 29,498,488 | 27,793,035 | 11,018,954 | 3,891,787 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $664.0K | $708.0K | $592.0K | $232.0K | $475.0K | $569.0K | $635.0K | |
| Other Non-cash | $11M | $-6M | $17M | $3M | $218.0K | $354.0K | $3M | |
| Operating Cash Flow | $-62M | $-69M | $-33M | $-42M | $-33M | $-15M | $-20M | |
| CapEx | $77.0K | $65.0K | $4M | $2M | $192.0K | $202.0K | $79.0K | |
| Investing Cash Flow | $-5M | $17M | $-20M | $47M | $-92M | $7M | $5M | |
| Financing Cash Flow | $66M | $40M | $66M | $5M | $110M | $16M | $1M | |
| Net Change in Cash | $-1M | $-12M | $13M | $11M | $-15M | $8M | $-14M | |
| Free Cash Flow | $-62M | $-69M | $-37M | $-44M | $-33M | $-16M | $-20M |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -40856.3% | -28899.6% | -15557.8% | -446.8% | · | -152.2% | -5445.0% | |
| Net Margin | -39009.5% | -27243.8% | -14274.5% | -436.5% | · | -155.2% | -5593.1% | |
| Pretax Margin | -39012.1% | -27243.4% | -14276.2% | -436.6% | · | -155.2% | -5631.0% | |
| EBITDA Margin | -40506.8% | -28598.3% | -15390.1% | -444.6% | · | -146.7% | -5294.6% | |
| ROA | -78.1% | -58.9% | -46.6% | -42.9% | -43.8% | -43.3% | -53.1% | |
| ROE | -107.8% | -79.7% | -62.2% | -50.2% | -47.9% | -61.4% | -98.5% | |
| ROIC | -115.0% | -97.0% | -60.6% | -64.9% | -31.1% | -50.3% | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.3 | 5.5 | 6.3 | 5.8 | 18.9 | 6.1 | 2.5 | |
| Quick Ratio | 0.7 | 0.7 | 1.4 | 0.7 | 0.4 | 2.9 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | 0.4 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.1 | · | 0.3 | 0.0 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.69 | $0.83 | $1.43 | $2.42 | $3.93 | $2.87 | $5.44 | |
| Revenue / Share | $0.00 | $0.00 | $0.01 | $0.37 | · | · | · | |
| Cash Flow / Share | $-0.67 | $-0.93 | $-0.62 | $-1.47 | · | · | · | |
| Cash / Share | $0.11 | $0.13 | $0.36 | $0.34 | $0.08 | $1.54 | $2.37 | |
| EPS (TTM) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | · |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -19.1% | -33.4% | -96.6% | · | · | · | · | |
| Revenue CAGR 3Y | -73.7% | · | -67.7% | · | · | · | · | |
| Revenue CAGR 5Y | -55.1% | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $190.0K | $235.0K | $353.0K | $10M | $0 | $10M | $422.0K | |
| Net Income TTM | $-74M | $-64M | $-50M | $-45M | $-34M | $-16M | $-16M | |
| Market Cap | $77M | $304M | $89M | $65M | $208M | $43M | $16M | |
| Enterprise Value | · | · | · | · | · | · | $16M | |
| P/E | -1.0 | -4.2 | -1.5 | -1.4 | -4.2 | -2.2 | · | |
| P/S | 404.0 | 1294.6 | 252.8 | 6.2 | · | 4.1 | 38.5 | |
| P/B | 1.1 | 4.3 | 1.0 | 0.9 | 1.9 | 1.4 | 0.8 | |
| P / Tangible Book | 1.1 | 4.3 | 1.0 | 0.9 | 1.9 | 1.4 | · | |
| P / Cash Flow | -1.2 | -4.4 | -2.7 | -1.5 | -6.3 | -2.8 | -0.8 | |
| P / FCF | -1.2 | -4.4 | -2.4 | -1.5 | -6.2 | -2.8 | -0.8 | |
| EV / EBITDA | · | · | · | · | · | · | -0.7 | |
| EV / FCF | · | · | · | · | · | · | -0.8 | |
| EV / Revenue | · | · | · | · | · | · | 37.3 | |
| Earnings Yield | -102.2% | -23.8% | -66.7% | -73.1% | -23.7% | -45.6% | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $190.0K | $0 | $0 | $0 | $0 | $0 | $235.0K | $353.0K | $0 | $0 | $0 | · | · | |
| R&D Expense | $7M | $7M | $11M | $22M | $15M | $12M | $12M | $15M | $14M | $13M | $10M | $10M | $9M | $10M | $9M | $9M | |
| SG&A Expense | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | |
| Operating Expenses | $11M | $11M | $15M | $27M | $20M | $16M | $16M | $18M | $17M | $17M | $13M | $14M | $13M | $13M | $13M | $12M | |
| Operating Income | $-11M | $-11M | $-15M | $-27M | $-20M | $-16M | $-16M | $-18M | $-17M | $-17M | $-13M | $-14M | $-13M | $-13M | $-13M | $-12M | |
| Other Non-op | $571.0K | $644.0K | $832.0K | $999.0K | $781.0K | $892.0K | $852.0K | $882.0K | $1M | $1M | $1M | $1M | $835.0K | $247.0K | $163.0K | $224.0K | |
| Net Income | $-10M | $-11M | $-14M | $-26M | $-20M | $-15M | $-15M | $-17M | $-16M | $-15M | $-11M | $-12M | $-12M | $-13M | $-12M | $-12M | |
| EPS (Basic) | $-0.11 | $-0.11 | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 | $-0.20 | $-0.22 | $-0.29 | $-0.46 | $-0.44 | $-0.44 | |
| EPS (Diluted) | $-0.11 | $-0.11 | $-0.15 | $-0.26 | $-0.22 | $-0.17 | $-0.17 | $-0.23 | $-0.23 | $-0.23 | $-0.20 | $-0.22 | $-0.29 | $-0.46 | $-0.44 | $-0.44 | |
| Shares (Basic) | 98,069,915 | 98,043,839 | · | 97,153,541 | 90,120,235 | 86,485,126 | · | 75,801,666 | 72,284,351 | 66,080,593 | 57,885,393 | 55,143,805 | 41,897,706 | 28,663,047 | 28,063,387 | 27,818,379 | |
| Shares (Diluted) | 98,069,915 | 98,043,839 | · | 97,153,541 | 90,120,235 | 86,485,126 | · | 75,801,666 | 72,284,351 | 66,080,593 | 57,885,393 | 55,143,805 | 41,897,706 | 28,663,047 | 28,063,387 | 27,818,379 | |
| EBITDA | $-11M | $-11M | · | $-27M | $-20M | $-16M | · | $-18M | $-17M | $-16M | $-13M | $-14M | $-13M | $-13M | $-13M | $-12M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $10M | $11M | $6M | $17M | $10M | $11M | $11M | $7M | $7M | $10M | $12M | $21M | $18M | $8M | $8M | |
| Short-term Investments | · | · | · | $79M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $518.0K | $586.0K | $677.0K | $2M | $7M | $6M | $8M | $8M | $10M | $10M | $3M | $5M | $3M | $6M | $4M | $4M | |
| Current Assets | $58M | $68M | $80M | $93M | $87M | $83M | $82M | $76M | $90M | $97M | $107M | $114M | $119M | $85M | $93M | $103M | |
| PP&E (Net) | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $5M | $1M | $558.0K | $433.0K | |
| PP&E (Gross) | · | · | $9M | · | · | · | $9M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $5M | · | · | · | $5M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $190.0K | $148.0K | $148.0K | $149.0K | $66.0K | $66.0K | $66.0K | $130.0K | $130.0K | $130.0K | $73.0K | $72.0K | $144.0K | $169.0K | $175.0K | $176.0K | |
| Total Assets | $70M | $80M | $93M | $107M | $102M | $97M | $97M | $92M | $106M | $113M | $125M | $133M | $137M | $96M | $96M | $105M | |
| Accounts Payable | $3M | $3M | $4M | $4M | $4M | $2M | $4M | $4M | $1M | $5M | $2M | $516.0K | $4M | $3M | $2M | $2M | |
| Accrued Liabilities | $7M | $7M | $10M | $10M | $10M | $8M | $9M | $9M | $9M | $10M | $10M | $11M | $9M | $7M | $7M | $4M | |
| Current Liabilities | $11M | $12M | $15M | $16M | $16M | $11M | $15M | $14M | $12M | $16M | $13M | $12M | $14M | $11M | $9M | $6M | |
| Capital Leases | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $11M | $12M | $12M | $13M | $13M | $12M | $7M | · | $133.0K | |
| Common Stock | $98.0K | $98.0K | $98.0K | $98.0K | $93.0K | $89.0K | $84.0K | $76.0K | $76.0K | $68.0K | $59.0K | $57.0K | $53.0K | $29.0K | $28.0K | $28.0K | |
| Paid-in Capital | $676M | $675M | $674M | $672M | $641M | $622M | $602M | $582M | $582M | $568M | $552M | $548M | $540M | $488M | $484M | $484M | |
| Retained Earnings | $-627M | $-617M | $-606M | $-592M | $-566M | $-547M | $-532M | $-517M | $-500M | $-484M | $-453M | $-442M | $-430M | $-410M | $-397M | $-384M | |
| AOCI | $-68.0K | $-70.0K | $-8.0K | $-1.0K | $-75.0K | $-66.0K | $-40.0K | $36.0K | $-168.0K | $-158.0K | $-294.0K | $-333.0K | $-248.0K | $-669.0K | $-810.0K | $-759.0K | |
| Stockholders' Equity | $49M | $58M | $67M | $80M | $75M | $75M | $70M | $65M | $82M | $84M | $98M | $106M | $110M | $77M | $87M | $99M | |
| Liabilities + Equity | $70M | $80M | $93M | $107M | $102M | $97M | $97M | $92M | $106M | $113M | $125M | $133M | $137M | $96M | $96M | $105M | |
| Shares Outstanding | 98,087,425 | 98,051,212 | 98,031,104 | 97,986,634 | 92,871,182 | 89,002,825 | 84,038,922 | 75,811,286 | 75,796,198 | 68,354,033 | 58,560,061 | 57,046,172 | 53,339,611 | 29,009,382 | 28,127,458 | 28,056,249 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $168.0K | $162.0K | $166.0K | $165.0K | $166.0K | $167.0K | $175.0K | $178.0K | $177.0K | $178.0K | $176.0K | $161.0K | $80.0K | $49.0K | $63.0K | $81.0K | |
| Other Non-cash | · | $-2M | · | · | · | $-707.0K | · | · | · | $-7M | · | · | $11M | · | · | $2M | |
| Operating Cash Flow | $-9M | $-13M | $-12M | $-20M | $-14M | $-15M | $-13M | $-13M | $-20M | $-22M | $-10M | $-12M | $-590.0K | $-12M | $-9M | $-10M | |
| CapEx | $73.0K | $138.0K | $31.0K | $37.0K | $9.0K | $0 | $25.0K | $15.0K | $8.0K | $17.0K | $557.0K | $2M | $1M | $426.0K | $53.0K | $43.0K | |
| Investing Cash Flow | $15M | $11M | $16M | $-20M | $3M | $-4M | $-6M | $18M | $7M | $-1M | $4M | $-4M | $-38M | $21M | $10M | $15M | |
| Financing Cash Flow | $-129.0K | $-142.0K | $-131.0K | $30M | $18M | $19M | $19M | $-105.0K | $13M | $8M | $3M | $8M | $49M | $3M | $39.0K | $1M | |
| Net Change in Cash | $6M | $-1M | $4M | $-11M | $7M | $-1M | $-378.0K | $5M | $-321.0K | $-16M | $-2M | $-8M | $11M | $11M | $893.0K | $6M | |
| Free Cash Flow | · | $-13M | · | · | · | $-15M | · | · | · | $-22M | · | · | $-2M | · | · | $-10M |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -14076.3% | · | · | · | · | · | -7079.1% | -3573.7% | · | · | · | · | · | |
| Net Margin | · | · | · | -13549.5% | · | · | · | · | · | -6591.9% | -3212.5% | · | · | · | · | · | |
| EBITDA Margin | · | · | · | -14076.3% | · | · | · | · | · | -7003.4% | -3573.7% | · | · | · | · | · | |
| ROA | -12.0% | -12.2% | · | -26.0% | -18.8% | -14.1% | · | -15.9% | -13.7% | -12.4% | -10.3% | -10.8% | -9.9% | -12.0% | -17.1% | -15.2% | |
| ROE | -16.7% | -16.2% | · | -35.4% | -25.0% | -18.7% | · | -21.1% | -17.4% | -15.9% | -12.9% | -12.8% | -11.5% | -13.6% | -19.5% | -16.4% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 5.8 | · | 5.9 | 5.6 | 7.8 | · | 5.4 | 7.6 | 6.1 | 8.3 | 9.3 | 8.7 | 7.5 | 10.1 | 16.4 | |
| Quick Ratio | 1.4 | 0.9 | · | 5.4 | 1.1 | 1.0 | · | 0.8 | 0.6 | 0.4 | 0.8 | 1.0 | 1.5 | 1.6 | 0.9 | 1.3 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.50 | $0.59 | · | $0.82 | $0.81 | $0.84 | · | $0.86 | $1.08 | $1.24 | $1.68 | $1.86 | $2.06 | $2.66 | $3.08 | $3.51 | |
| Revenue / Share | · | · | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | $0.01 | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.13 | · | · | · | $-0.18 | · | · | · | $-0.34 | · | · | $-0.01 | · | · | · | |
| Cash / Share | $0.16 | $0.10 | · | $0.06 | $0.19 | $0.12 | · | $0.15 | $0.09 | $0.10 | $0.17 | $0.22 | $0.39 | $0.63 | $0.30 | $0.30 | |
| EPS (TTM) | $-0.63 | $-0.74 | · | $-0.82 | $-0.79 | $-0.80 | · | $-0.92 | $-0.89 | $-0.88 | $-0.97 | $-1.23 | $-1.45 | $-1.54 | $-1.50 | $-1.70 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $190.0K | $190.0K | · | $190.0K | $0 | $0 | · | $235.0K | $588.0K | $588.0K | $11M | $10M | · | · | $10M | $10M | |
| Net Income TTM | $-61M | $-70M | · | $-75M | $-67M | $-63M | · | $-64M | $-58M | $-54M | $-43M | $-45M | $-45M | $-46M | $-41M | $-39M | |
| Market Cap | $59M | $76M | · | $71M | $471M | $269M | · | $133M | $118M | $133M | $93M | $123M | $112M | $87M | $80M | $150M | |
| P/E | -0.9 | -1.1 | · | -0.9 | -6.4 | -3.8 | · | -1.9 | -1.8 | -2.2 | -1.6 | -1.8 | -1.4 | -1.9 | -1.9 | -3.1 | |
| P/S | 308.2 | 402.5 | · | 371.8 | · | · | · | 567.8 | 201.1 | 226.7 | 8.6 | 11.9 | · | · | 7.6 | 14.4 | |
| P/B | 1.2 | 1.3 | · | 0.9 | 6.3 | 3.6 | · | 2.0 | 1.4 | 1.6 | 0.9 | 1.2 | 1.0 | 1.1 | 0.9 | 1.5 | |
| P / Tangible Book | 1.2 | 1.3 | · | 0.9 | 6.3 | 3.6 | · | 2.0 | 1.4 | 1.6 | 0.9 | 1.2 | 1.0 | 1.1 | 0.9 | 1.5 | |
| P / Cash Flow | · | -6.1 | · | · | · | -17.4 | · | · | · | -6.0 | · | · | -189.9 | · | · | -14.8 | |
| Earnings Yield | -105.5% | -94.9% | · | -113.7% | -15.6% | -26.5% | · | -52.3% | -57.0% | -45.1% | -61.4% | -56.9% | -69.0% | -51.3% | -53.0% | -31.8% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $190.0K | $235.0K | $353.0K | $10M | $0 |
| Margem Operacional % | -40856.3% | -28899.6% | -15557.8% | -446.8% | · |
| Lucro líquido | $-74M | $-64M | $-50M | $-45M | $-34M |
| EPS Diluído | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 5.3 | 5.5 | 6.3 | 5.8 | 18.9 |
| Índice de Liquidez Seca | 0.7 | 0.7 | 1.4 | 0.7 | 0.4 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-62M | $-69M | $-37M | $-44M | $-33M |
Investidores institucionais (13F) 108 declarantes · $26.7M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 17 (-22 vs trimestre anterior) | 34 (+26 vs trimestre anterior) | 32 (+4 vs trimestre anterior) | 32 (-4 vs trimestre anterior) | -17.3M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| FEDERATED HERMES, INC. | $5.078.576 | 8.509.678 | 19,04% | Ações |
| VANGUARD GROUP INC | $3.885.145 | 4.961.871 | 14,57% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.273.430 | 3.808.091 | 8,52% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $1.557.975 | 2.610.548 | 5,84% | Ações |
| FMR LLC | $1.474.942 | 2.471.418 | 5,53% | Ações |
| BlackRock, Inc. | $1.090.552 | 1.827.332 | 4,09% | Ações |
| Kalehua Capital Management LLC | $1.067.178 | 1.788.167 | 4,00% | Ações |
| JANE STREET GROUP, LLC | $1.027.270 | 1.721.297 | 3,85% | Ações |
| UBS Group AG | $914.097 | 1.531.151 | 3,43% | Ações |
| MORGAN STANLEY | $801.882 | 1.343.636 | 3,01% | Ações |
| TWO SIGMA INVESTMENTS, LP | $743.104 | 1.245.147 | 2,79% | Ações |
| CITADEL ADVISORS LLC | $741.265 | 1.242.067 | 2,78% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $702.734 | 1.177.020 | 2,63% | Ações |
| TWO SIGMA ADVISERS, LP | $658.861 | 841.350 | 2,47% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $445.833 | 747.039 | 1,67% | Ações |
| MILLENNIUM MANAGEMENT LLC | $391.531 | 656.051 | 1,47% | Ações |
| GOLDMAN SACHS GROUP INC | $382.672 | 641.208 | 1,43% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $343.947 | 576.125 | 1,29% | Ações |
| STATE STREET CORP | $295.387 | 494.951 | 1,11% | Ações |
| H D Vest Advisory Services | $292.382 | 57.669 | 1,10% | Ações |
| MARSHALL WACE, LLP | $220.872 | 368.120 | 0,83% | Ações |
| WOLVERINE TRADING, LLC | $163.096 | 205.100 | 0,61% | Opção de compra |
| CITADEL ADVISORS LLC | $148.603 | 249.000 | 0,56% | Opção de compra |
| XTX Topco Ltd | $135.281 | 226.678 | 0,51% | Ações |
| NORTHERN TRUST CORP | $131.380 | 220.141 | 0,49% | Ações |
| BANK OF AMERICA CORP /DE/ | $123.650 | 207.468 | 0,46% | Ações |
| WOLVERINE TRADING, LLC | $110.453 | 138.900 | 0,41% | Opção de venda |
| JANE STREET GROUP, LLC | $106.588 | 178.600 | 0,40% | Opção de compra |
| RENAISSANCE TECHNOLOGIES LLC | $98.604 | 165.222 | 0,37% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92.880 | 154.800 | 0,35% | Opção de compra |
| JPMORGAN CHASE & CO | $85.337 | 150.666 | 0,32% | Ações |
| GROUP ONE TRADING LLC | $82.882 | 138.878 | 0,31% | Ações |
| Qube Research & Technologies Ltd | $75.791 | 126.996 | 0,28% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $69.900 | 116.500 | 0,26% | Opção de venda |
| DIMENSIONAL FUND ADVISORS LP | $54.114 | 90.861 | 0,20% | Ações |
| WOLVERINE TRADING, LLC | $42.961 | 54.026 | 0,16% | Ações |
| HSBC HOLDINGS PLC | $38.361 | 66.185 | 0,14% | Ações |
| Mariner, LLC | $34.998 | 58.658 | 0,13% | Ações |
| CITADEL ADVISORS LLC | $34.137 | 57.200 | 0,13% | Opção de venda |
| HOHIMER WEALTH MANAGEMENT, LLC | $32.824 | 55.000 | 0,12% | Ações |
| MERCER GLOBAL ADVISORS INC /ADV | $31.947 | 53.531 | 0,12% | Ações |
| KINGSWOOD WEALTH ADVISORS, LLC | $31.034 | 52.000 | 0,12% | Ações |
| Schonfeld Strategic Advisors LLC | $30.364 | 50.880 | 0,11% | Ações |
| ADAR1 Capital Management, LLC | $30.249 | 50.685 | 0,11% | Ações |
| Alpha Wealth Funds, LLC | $29.890 | 50.000 | 0,11% | Ações |
| Tower Research Capital LLC (TRC) | $29.105 | 48.768 | 0,11% | Ações |
| CWM, LLC | $28.088 | 36.010 | 0,11% | Ações |
| Creative Planning | $24.823 | 41.593 | 0,09% | Ações |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $23.925 | 43.948 | 0,09% | Ações |
| Point72 Asset Management, L.P. | $22.248 | 37.278 | 0,08% | Ações |
Ativistas e proprietários de 5%+ 3 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| PAUL SCHIMMEL, PAUL SCHIMMEL PROTOTYPE PSP, PAUL SCHIMMEL, TRUSTEE, FBO PAUL SCHIMMEL ×3 declarações | 14 de Fevereiro de 2020 | · | Declaração inicial | · | SEC |
| Polaris Venture Partners V, L.P. (“PVP V”), Polaris Venture Partners Entrepreneurs’ Fund V, L.P. (“PVPE V”), Polaris Venture Partners Founders’ Fund V, L.P. (“PVPFF V”), Polaris Venture Partners Special Founders’ Fund V, L.P. (“PVPSFF V”), Polaris Venture Management Co. V, L.L.C. (“PVM V”), Jonathan A. Flint, Terrance G. McGuire, Amir Nashat ×2 declarações | 17 de Julho de 2019 | · | Declaração inicial | · | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×3 declarações | 12 de Fevereiro de 2019 | · | Declaração inicial | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 34 insiders · 18 diretores · 12 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Sanjay Shukla | President and CEO | 3 de Fevereiro de 2026 M | 153.553 | 0 | 1 | $-3.670 |
| Brandon Yaras | Chief Financial Officer | 1 de Outubro de 2026 A | · | 0 | 0 | $0 |
| Jill Marie Broadfoot | Chief Financial Officer | 3 de Fevereiro de 2026 M | 37.296 | 0 | 1 | $-1.527 |
| Stan Blackburn | Acting Chief Financial Officer | 27 de Janeiro de 2016 A | · | 0 | 0 | $0 |
| Frederic Chereau | President & COO | 6 de Maio de 2015 A | · | 0 | 0 | $0 |
| Nancy Krueger | General Counsel | 3 de Fevereiro de 2026 M | 33.124 | 0 | 1 | $-1.096 |
| Ashraf Amanullah | Senior Vice President, Biologics Development and Manufacturing | 31 de Maio de 2018 M | 26.264 | 0 | 0 | $0 |
| John T Blake | Senior Vice President, Finance | 7 de Fevereiro de 2018 M | 1.932 | 0 | 0 | $0 |
| David John King | Chief Scientific Officer | 6 de Fevereiro de 2018 A | · | 0 | 0 | $0 |
| Sanuj K. Ravindran | Chief Business Officer | 7 de Fevereiro de 2017 A | · | 0 | 0 | $0 |
| Andrew Cubitt | VP, Product Protection | 13 de Setembro de 2016 A | · | 0 | 0 | $0 |
| Kelly Blackburn | VP, Clinical Affairs | 28 de Março de 2016 A | · | 0 | 0 | $0 |
| Melissa A. Ashlock | SVP, Translational Medicine and Therapeutics | 27 de Janeiro de 2016 A | · | 0 | 0 | $0 |
| John C. Mckew | VP, Research | 27 de Janeiro de 2016 A | · | 0 | 0 | $0 |
| Holly D. Chrzanowski | VP, Enterprise Talent & Organization | 27 de Janeiro de 2016 A | · | 0 | 0 | $0 |
| Marcy Graham | VP, Investor Relations and Corporate Communications | 4 de Janeiro de 2016 A | · | 0 | 0 | $0 |
| Fred Ramsdell | VP, Immunology | 1 de Outubro de 2015 A | · | 0 | 0 | $0 |
| David M. Weiner | Chief Medical Officer | 6 de Maio de 2015 A | · | 0 | 0 | $0 |
| SCHIMMEL PAUL | Conselheiro | 27 de Maio de 2026 P | 779.143 | 3 | 0 | $962.720 |
| Svetlana Lucas | Conselheiro | 11 de Maio de 2026 A | 6.000 | 0 | 0 | $0 |
| Jane A Gross | Conselheiro | 11 de Maio de 2026 A | 9.750 | 0 | 0 | $0 |
| Eric Benevich | Conselheiro | 11 de Maio de 2026 A | · | 0 | 0 | $0 |
| Sara Zaknoen | Conselheiro | 11 de Maio de 2026 A | 6.000 | 0 | 0 | $0 |
| John K Clarke | Conselheiro | 22 de Maio de 2024 A | 19.797 | 0 | 0 | $0 |
| Jeffrey S. Hatfield | Conselheiro | 6 de Maio de 2020 A | · | 0 | 0 | $0 |
| John Mendlein | Conselheiro | 8 de Maio de 2019 A | 615.382 | 0 | 0 | $0 |
| BLAIR JAMES C | Conselheiro | 8 de Maio de 2019 A | · | 0 | 0 | $0 |
| Amir Nashat | Conselheiro | 15 de Maio de 2018 A | 17.638 | 0 | 0 | $0 |
| Kathryn E Falberg | Conselheiro | 24 de Maio de 2016 A | · | 0 | 0 | $0 |
| EcoR1 Capital Fund Qualified, L.P. | Detentor de 10% | 16 de Maio de 2018 S | 0 | 0 | 0 | $0 |
| Timothy Coughlin | · | 11 de Maio de 2026 A | 56.000 | 0 | 0 | $0 |
| Mark Alan Goldberg | · | 9 de Maio de 2017 A | · | 0 | 0 | $0 |
| Srinivas Akkaraju | · | 9 de Maio de 2017 A | 1.866.126 | 0 | 0 | $0 |
| Grove Matsuoka | · | 7 de Fevereiro de 2017 A | 12.412 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 2 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
ATYR Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
Preço-alvo de 12 meses
7 analistas · 2026-10-01Alvo médio $2.86 +894,8%
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.